In May 2025, the FDA issued a detailed warning letter to Staska Pharmaceuticals, an outsourcing facility registered under Section 503B of the Federal Food, Drug, and Cosmetic Act (FDCA). The letter outlined numerous violations — from inadequate aseptic practices and poor documentation to failure to meet CGMP requirements and labeling deficiencies.
For compounding pharmacies and outsourcing facilities, this warning letter is a cautionary tale and a roadmap for what not to do. But more importantly, it’s an opportunity to learn, prepare, and ensure your facility is inspection-ready at all times.
Key Takeaways from the FDA Warning Letter
Failure to Meet 503B Requirements
-Use of bulk drug substances from unregistered establishments
-Incomplete or non-compliant labeling (missing MedWatch info, directions for use)
CGMP Violations
– Inadequate media fill protocols and aseptic process simulations
– Personnel reaching beyond their elbows into ISO 5 areas
– Insufficient environmental monitoring and gowning practices
– Lack of validated cleaning and sanitization procedures
Investigational Failures
– Recalls were not thoroughly investigated
– Defective vial issues not traced to other potentially impacted lots
– Failure to expand investigations or identify systemic root causes
– Draft procedures submitted instead of finalized, implemented SOPs
– No justification for inspection alert/action limits
– Incomplete or missing CAPA documentation and training records
Recommendations: How to Stay Prepared and Compliant
Whether you’re a 503A pharmacy, 503B outsourcing facility, or planning to scale sterile compounding operations, consider these action items:
1. Verify All Suppliers
– Only use bulk drug substances from FDA-registered establishments.
– Maintain an Approved Supplier List (ASL) that is reviewed regularly.
2. Ensure Complete, Compliant Labeling
– Include required elements such as dosage, administration, and MedWatch reporting info.
– Conduct periodic label audits aligned with 503B(a)(10).
3. Strengthen Aseptic Technique and Environmental Monitoring
– Train personnel rigorously — and verify elbow placement in ISO 5 zones.
– Validate smoke studies under dynamic conditions, not static.
– Define and enforce proper gowning sequences and change intervals.
4. Validate Media Fills and Cleaning Protocols
– Simulate worst-case conditions (e.g., stuck plungers, prolonged operations).
– Validate all cleaning agents and equipment — don’t rely on assumptions.
5. Implement Robust CAPA and Deviation Management
– Expand investigations beyond the immediate issue.
– Always identify root cause, evaluate scope, and track CAPA implementation.
6. Finalize and Implement SOPs
– Drafts are not enough — SOPs must be reviewed, approved, and trained on.
– Track training completion and effectiveness with documented assessments.
How Avendium Can Help
At Avendium, we specialize in helping sterile compounding pharmacies and 503B outsourcing facilities stay compliant with FDA, CGMP, and 503B requirements. Our services include:
✅ Mock FDA Inspections & Readiness Audits
✅ 503B Gap Assessments
✅ Aseptic Processing & Media Fill Validation
✅ CAPA & Deviation System Implementation
✅ Environmental Monitoring Programs
✅ SOP Development & Staff Training
✅ Supplier Qualification & Risk Management
✅ Labeling Reviews & Regulatory Strategy
We know the regulations inside and out — and we’ll partner with you to prevent issues before they become warning letters.
Conclusion
FDA inspections are never easy — but they don’t have to be painful. With the right systems, partners, and proactive planning, you can stay compliant and protect both your business and your patients.
If you’re unsure whether your facility would pass an inspection today, let’s talk. A 30-minute call with Avendium could save you months of remediation and thousands in legal costs.
Contact us today to schedule a compliance assessment.
Sources: